Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome.

Spagnuolo, R; Cosco, C; Mancina, R M; Ruggiero, G; Garieri, P; Cosco, V; Doldo, P

Spagnuolo, R; Cosco, C; Mancina, R M; Ruggiero, G; Garieri, P; Cosco, V; Doldo, P.

Affiliation

Spagnuolo R; Department of Surgery and Medical Science, IBD Unit, University "Magna Graecia", Campus "Salvatore Venuta", Catanzaro, Italy. spagnuolo@unicz.it.

Eur Rev Med Pharmacol Sci ; 21(2 Suppl): 102-107, 2017 06.

Article in En | MEDLINE | ID: mdl-28724171

Subject(s)

Enzyme Therapy; Inflammatory Bowel Diseases/complications; Inflammatory Bowel Diseases/drug therapy; Inositol/therapeutic use; Irritable Bowel Syndrome/complications; Irritable Bowel Syndrome/drug therapy; Quality of Life; beta-Glucans/therapeutic use; Abdominal Pain/complications; Abdominal Pain/drug therapy; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use; Biological Factors/therapeutic use; Drug Combinations; Drug Therapy, Combination; Female; Flatulence/complications; Flatulence/drug therapy; Gastrointestinal Agents/therapeutic use; Humans; Male; Mesalamine/therapeutic use; Middle Aged

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Inflammatory Bowel Diseases / Irritable Bowel Syndrome / Beta-Glucans / Enzyme Therapy / Inositol Type of study: Clinical_trials / Risk_factors_studies Aspects: Patient_preference Limits: Female / Humans / Male / Middle aged Language: En Journal: Eur Rev Med Pharmacol Sci Journal subject: FARMACOLOGIA / TOXICOLOGIA Year: 2017 Document type: Article Affiliation country: Italy

Search on Google

Add to My VHL

XML

PubMed Links